Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 65

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 65
---
3.20 price per unit (the “Second Private Placement Offering”),
where each unit (a “Unit” and collectively the “Units”) comprised of (i) two (2) shares of the Common Stock and
(ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock exercisable until December
31, 2026, at a per share exercise price of $2.40. In consideration of proceeds in the amount of $4,631.25 thousands received from the
subscribers in the Second Private Placement Offering, we issued to these investors an aggregate of 2,894,532 of the Company’s Common
Stock and warrants to purchase an additional 1,447,266 shares of Common Stock.

The shares of Common Stock sold in the above
offerings and warrants to purchase Common Stock issued by the Company to these investors are included in this registration statement
of which this Prospectus is a part thereof.

Key Financial Terms and Metrics

The following discussion summarizes the key factors
our management believes are necessary for an understanding of our consolidated financial statements.

Revenues

We have not generated any revenues from product
sales to date.

Research and Development Expenses

The process of researching and developing our
product candidates is lengthy, unpredictable and subject to many risks. We expect to continue incurring substantial expenses for the
next several years as we continue to develop our product candidates. We are unable, with any certainty, to estimate either the costs
or the timelines in which those expenses will be incurred. Our current development plans focus on the development of a novel technology
related to Nano-Liposomal Particles (NLP). The design and development of these pharmaceutical solutions will consume a large proportion
of our current, as well as projected, resources.

Our research and development costs are comprised
of:

| ● | internal recurring costs,                                                                                                              
 such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities 
 and maintenance costs attributable to research and development functions; and                                                          |
| ● | fees paid to external parties                                                                                                          
 who provide us with contract services, such as preclinical testing, manufacturing, related testing and preparation for clinical trial  
 activities.                                                                                                                            |

General and Administrative Expenses

General and administrative expenses consist primarily
of salaries, employee benefits, equity compensation and other personnel-related costs associated with executive, administrative and other
support staff. Other significant general and administrative expenses include the costs associated with professional fees for accounting,
auditing,